Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • Feb 28, 2014

Press release | Regulated information

IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, 28 February 2014 - IBA (Ion Beam Applications SA), the global hightech leader in next generation radiation therapy and diagnostics for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated 28 February 2014.

Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Communication of the basic data as per Article 15 §1 al.1 of the Law

Total capital: Total number of securities conferring the voting right:	EUR 38 832 558.90 27 667 636 (of which
	27 667 636
Total number of securities conferring the voting right, by category:	N/A
Total number of voting rights, by category:	N/A
	0
Total number of rights, materialized or not by certificates, giving the right to subscribe to newly issued securities conferring the voting right
(e.g. warrants):	2 180 138
	12 702 489 with VVPR strips) Total number of voting rights (= the denominator): Communication of the additional data as per Article 15 §1 al.2 of the Law Total number of convertible bonds conferring the voting right:

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent.

- Ends -

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Press release | 28 February 2014 1 | 2

Press release |

Regulated information

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact person

IBA Caroline Hardy Corporate Legal Counsel +32 10 201 159 caroline.hardy@iba-group.com

Press release | 28 February 2014 2 | 2